Novocure Ltd (NVCR)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Novocure Ltd currently loses $9.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 4 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Novocure beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 23, 2026, with revenue rising 15.6% year over year to about $183.6 million as its tumor treating fields (TTFields) device portfolio (including Optune Gio, Optune Lua, and Optune Pax) drove results. On the consensus read-through, revenue of $183.6 million topped the $172.4 million estimate, +6.5%, while EPS of -$0.13 topped the -$0.33 estimate by $0.20, improving from -$0.36 a year ago (+63.9% YoY). Gross profit came in at roughly $142.5 million, translating to a gross margin of about 78%, and operating income was around -$10.6 million for an operating margin of -5.8%. The company posted a net loss of about $15.7 million, narrowing from a net loss of $40.1 million a year ago (+61.0% YoY), and it generated operating cash flow of roughly $12.4 million during the quarter. Consensus for the next period calls for EPS of -$0.23 on revenue of $182.3 million.
Next report — what to expect
Novocure Ltd (NVCR) reports on October 29, 2026. The next-period consensus calls for EPS of -$0.245 on revenue of $182.3 million. For trailing context, revenue grew +15.6% year over year last quarter. Novocure has beaten EPS in 6 of 8 most recent quarters.
About Novocure Ltd
Novocure Ltd is a healthcare company listed on NASDAQ as NVCR that develops, manufactures, and commercializes tumor treating fields (TTFields) devices for solid tumor cancers. Its device portfolio includes Optune Gio, Optune Lua, and Optune Pax, and the business generated $655.4 million in FY2025 revenue.
Today's Snapshot
NVCR closed 2.8% lower at 14.68, in line with a weaker sector. NVCR reports earnings on 29 October.
Trading Volume
Below 10d avg (1.5M)
1.1M
vs S&P 500 Today
Underperforming Market
-2.26%
Updated: October 23, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$14.77 - $15.74Sell
- RSI (14)44.22Neutral
- Stochastic %K (14, 3, 3)56.93Neutral
- MACD Level (12, 26)-0.32Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.